

Disclosures

Personal Commercial (13)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
Self			
Akcea	Consultant Fees/Honoraria	Significant (>= \$5,000)	Prevention
Allergan	Research/Research Grants ‡ <i>Armour ThyROID Compared to Synthetic t4 in Hypothyroid patients</i>	Modest (< \$5,000)	Other
Amarin	Speaker's Bureau	Significant (>= \$5,000)	Prevention
Amarin	Consultant Fees/Honoraria	Significant (>= \$5,000)	Prevention
Amgen Inc.	Speaker's Bureau	Significant (>= \$5,000)	Prevention
Dexcom	Research/Research Grants ‡ <i>Continuous Blood Glucose Monitoring (G7) device study in type 1 diabetes, Dexcom, 2019</i>	Significant (>= \$5,000)	Other
Eli Lilly and Company	Research/Research Grants ‡ <i>SURPASS-4 GLP-1 RA-Glucose-dependent insulinotropic polypeptide (GIP) Cardiovascular Risk Study</i>	Significant (>= \$5,000)	Other
Ionis (Akcea)	Research/Research Grants ‡ <i>The APPROACH extension study, Volanesoren (ISIS 304801, APOC3 antisense oligonucleotide, Extension to Early Access Program 2016-2019 Ionis ISIS 304801-CS7 NCT02658175</i>	Significant (>= \$5,000)	Prevention
Merck & Co., Inc.	Speaker's Bureau	Significant (>= \$5,000)	Other
Mylan Inc.	Research/Research Grants ‡ <i>Phase 3 T1DM study – Mylan's generic insulin aspart study, Mylan MYL-1601D-3001</i>	Significant (>= \$5,000)	Other
Novo Nordisk Inc.	Research/Research Grants ‡ <i>How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People with Type 2 Diabetes (FOCUS)</i>	Significant (>= \$5,000)	Other
Novo Nordisk Inc.	Research/Research Grants ‡ <i>How Well Semaglutide Works Compared to Liraglutide in People Living with Overweight or Obesity (STEP 8)</i>	Significant (>= \$5,000)	Other
Novo Nordisk Inc.	Research/Research Grants ‡ <i>Obesity / weight loss / STEP 3 study – semaglutide, A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes</i>	Significant (>= \$5,000)	Other

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (0)

No disclosures on record

Clinical Trial Enroller (0)

No disclosures on record

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (0)

No disclosures on record

Agreement

Certified Education Attestation | Signed on 1/31/2020

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

Confidentiality, Disclosure and Assignment Agreement | Signed on 1/31/2020

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

Embargo | Signed on 1/31/2020

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

On-Going Obligation Agreement | Signed on 3/12/2020

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.